HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for Intermediate Risk HPV-16-associated Head and Neck Squamous Cell Carcinoma
Phase II Study Evaluating HPV-16 Vaccination (ISA101b) and Pembrolizumab Plus Cisplatin Chemoradiotherapy for Intermediate Risk HPV-16 Associated Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: Dan Zandberg
Listed as NCT04369937, this PHASE2 trial focuses on HPV-Related Squamous Cell Carcinoma and Head and Neck Squamous Cell Carcinoma and remains ongoing. Sponsored by Dan Zandberg, it has been updated 12 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Oct 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Nov 2024 — Oct 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Sep 2022 — Oct 2023 [monthly]
Recruiting PHASE2
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Oct 2021 — Jun 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Aug 2020 — Nov 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Dan Zandberg
- ISA Pharmaceuticals
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .